Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced NSCLC × aflutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

NSCLC 5 Carcinoma, Non-Small-Cell Lung 4 Respiratory Tract Neoplasms 1 Lung Neoplasms 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1 Bronchial Neoplasms 1 Advanced Non-small Cell Lung Cancer 1 Advanced NSCLC Patients With T790M 1 Advanced NSCLC 1 Advanced Lung Cancer 1

Interventions

famitinib 1 camrelizumab 1 aflutinib 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03127449 2025-04-03

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Allist Pharmaceuticals, Inc.

Phase NA Terminated

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡